Content area
Abstract
Four distinct species of human coronaviruses (HCoVs) circulate in humans. Despite the recent attention due to SARS-CoV-2, a comprehensive understanding of the molecular epidemiology and genomic evolution of HCoVs remains unclear. Here, we employed primary differentiated human nasal epithelial cells for the successful isolation and genome sequencing of HCoVs derived from two retrospective cohorts in Singapore and Tanzania. Phylodynamic inference shows that HCoV-229E and HCoV-OC43 were subject to stronger genetic drift and reduced purifying selection from the early 2000s onwards, primarily targeting spike Domain A and B. This resulted in increased lineage diversification, coinciding with a higher effective reproductive number (Re>1.0). However, HCoV-NL63 and HCoV-HKU1 experienced weaker genetic drift and selective pressure with prolonged regional persistence. Our findings suggest that HCoV-229E and HCoV-OC43 viruses are adept at generating new variants and achieving widespread intercontinental dissemination driven by continuous genetic drift, recombination, and complex migration patterns.
Details
1 Duke-NUS Medical School, 8 College Road, Programme in Emerging Infectious Diseases, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
2 Duke-NUS Medical School, 8 College Road, Programme in Emerging Infectious Diseases, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Iowa State University, Veterinary Diagnostic and Production Animal Medicine, Ames, IA, USA (GRID:grid.34421.30) (ISNI:0000 0004 1936 7312)
3 Kilimanjaro Christian Medical Centre, Moshi, Tanzania (GRID:grid.415218.b) (ISNI:0000 0004 0648 072X); Kilimanjaro Christian Medical University College, Moshi, Tanzania (GRID:grid.412898.e) (ISNI:0000 0004 0648 0439)
4 Kilimanjaro Christian Medical Centre, Moshi, Tanzania (GRID:grid.415218.b) (ISNI:0000 0004 0648 072X); Kilimanjaro Christian Medical University College, Moshi, Tanzania (GRID:grid.412898.e) (ISNI:0000 0004 0648 0439); University of Otago, Centre for International Health, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830); Duke University, Division of Infectious Diseases and International Health, Department of Medicine, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961); Duke University, Duke Global Health Institute, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
5 Duke-NUS Medical School, 8 College Road, Programme in Emerging Infectious Diseases, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); University of Otago, Centre for International Health, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830); Singapore General Hospital, Department of Infectious Diseases, Singapore, Singapore (GRID:grid.163555.1) (ISNI:0000 0000 9486 5048); National University of Singapore, Department of Otolaryngology, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
6 Duke-NUS Medical School, 8 College Road, Programme in Emerging Infectious Diseases, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Singapore General Hospital, Department of Infectious Diseases, Singapore, Singapore (GRID:grid.163555.1) (ISNI:0000 0000 9486 5048)
7 National University of Singapore, Department of Otolaryngology, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
8 Duke-NUS Medical School, 8 College Road, Programme in Emerging Infectious Diseases, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Duke-NUS Medical School, Centre for Outbreak Preparedness, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)




